

*Biographical sketch and personal statement*

**Lawrence B. Faulkner, M.D.**

Title: Medical Advisory Board Coordinator, Cure2Children Foundation

*Specialty: Pediatric hematology-oncology and stem cell transplantation*

Born August 3, 1958

lawrence.faulkner@cure2children.org



**Education**

Medical Doctor Degree: University of Florence, Italy , 1983 (110/110 cum laude).

Pediatric Residency: Long Island College Hospital , Brooklyn NY, 1986-89.

Pediatric Hematology-Oncology Fellowship: Memorial Sloan Kettering Cancer Center - New York Hospital, New York NY, Cornell University Medical School combined program, 1989-92.

**International Memberships**

International Society of Pediatric Oncology

American Society of Hematology

American Society of Clinical Oncology

**Work experience**

1990-1992 Pediatric Fellow in the laboratory of Developmental Hematology directed by Malcolm A. S. Moore Ph.D., Memorial Sloan Kettering Cancer Center, NY, USA.

1992-1993 Pediatric Hematology-Oncology attending at the Catholic University Medical Center (Policlinico Gemelli) in Rome, Italy.

1994-2005. Pediatric Hematology-Oncology attending at the Children's Hospital of Florence (Ospedale Meyer).

2006-present. Medical Coordinator of the Cure2Children Foundation.

**Research Grants and Awards**

1995 Principal investigator of a three-year "Seed Grant" by the Italian Cancer Research Association. Total funds: 90,000 Euros.

1997 Principal investigator of a four-year research project by the Italian Neuroblastoma Research Association on minimal residual disease analysis of neuroblastoma. Total funds: 80,000 Euros.

2001 Principal investigator of a four-year research support by the Tommasino Bacciotti Foundation on the use of stem cell transplantation for the cure of high-risk brain tumors and other pediatric malignancies. Total funds: 200,000 Euros.

2002 Coordinator of the Marrow Disease Evaluation Subcommittee of the Neuroblastoma Group of the International Society of Pediatric Oncology (SIOP).

2007 Founder and Advisory Board Coordinator of the Cure2Children Foundation

2008 Principal investigator for a two-year grant from the *Fondazione Monte dei Paschi di Siena*, Italy, to support a network of centers offering the cure for thalassemic children in Pakistan. Total funds: 150,000 Euros.

2010 Principal investigator for a one-year grant from the *Fondazione Monte dei Paschi di Siena*, Italy, on the support for sustainable cure and prevention of thalassemia in India through social entrepreneurship initiatives. Total funds: 20,000 Euros.

2010 Coordinator of a two-year grant of 50,000,000 Pakistani rupees (~450,000 Euros) from the Pakistani-Italian Dept-for-development Swap Agreement for a project on the cure and prevention of thalassemia in Pakistan.

2010 Coordinator of a two-year grant for a Global Neuroblastoma Database module within the St Jude's Hospital Outreach Program Pediatric Oncology Network Database by the *Fondazione Umberto Veronesi*, Italy. Total funds: 122,000 Euros.

### **Abstracts and meeting presentations 2010-2013**

**Faulkner L**, Hussain MH, El Missiry M, Khalid S, Yaqub N, Khan Gilani S, Fatima I, et al. Online and On-site Focused Training to Launch New BMT Services in Emerging Countries: Summary of Outcomes and Costs. presented at the 39th Annual Meeting of the *European Group for Blood and Marrow Transplantation*, London, UK, April 2013. >> [online abstract](#)

Mehta, PA and **Faulkner L**. Hematopoietic Cell Transplantation for Thalassemia: A Global Perspective. *Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation* 19(1 Suppl) (2013): S70–3.

**Faulkner L**. Extending access to cure of hemoglobinopathies in lower income countries: The preliminary experience of the Cure2Children Foundation in Pakistan. *Roundtable presentation at the Global Health Council's 38th Annual International Conference Washington, D.C. USA, June 13-17, 2011*.

**Faulkner L**. Transplantation in low resource countries. *Oral presentation at the [12th International Conference on Thalassaemia and Haemoglobinopathies](#), Antalya, Turkey, 11-14 May 2011*.

Yaqub N, Khalid S, Zahra T and **Faulkner L**. Second BMT for thalassemia major using post-transplant cyclophosphamide only as GVHD/rejection prophylaxis. *Poster presentation at the [2011 annual meeting of the European group for Blood and Marrow Transplantation](#), Paris, France 3-6 April 2011*.

Ansari S, Shamsi T, Khalid S, Yaqub N, Rashid K, Farzana T, Iqbal Y, Zahra T, Choudhry S, Sodani P, Gallucci C, Erer B, and **Faulkner L**. Extending access to bone marrow transplantation to low-income countries: The preliminary experience of the Cure2Children Foundation in Pakistan. *Pediatric Blood & Cancer*, 55 (5):PN012, 2010.

Ansari S, Shamsi T, Khalid S, Yaqub N, Rashid K, Farzana T, Iqbal Y, Sodani P, Gallucci C, Erer B, and **Faulkner L**. Safe and effective reduced-cost bone marrow transplantation for thalassaemia: preliminary experience of the Cure2Children Foundation in Pakistan. *Bone Marrow Transplant*, vol. 45 (suppl.2), P695. 2010.

### **Scientific publications**

[\(Citation index\)](#)

Mehta, PA and **Faulkner L**. Hematopoietic Cell Transplantation for Thalassemia: A Global Perspective. *Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation* 19(1 Suppl) (2013): S70–3 (*Impact Factor: 3.873*).

**Faulkner L**, Yaqub N, Khalid S, Zhara T, Ansari S, Farzana T, Shamsi T: Transplantation in low resource countries. *Thalassemia Reports*, 2011 >> [open access article](#)

Sodani P, Isgrò A, Gaziev J, Polchi P, Paciaroni K, Marziali M, Simone MD, Roveda A, Montuoro A, Alfieri C, De Angelis G, Gallucci C, Erer B, Isacchi G, Zinno F, Adorno G, Lanti A, **Faulkner L**, Testi M, Andreani M, and Lucarelli G: Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. *Blood* 115 (6):1296-1302, 2010 (*Impact Factor: 9.898*).

Corrias MV, Parodi S, Haupt R, Lacitignola L, Negri F, Sementa AR, Dau D, Scuderi F, Carlini B, Bianchi M, Casale F, **Faulkner L**, Garaventa A. Detection of GD2 positive cells in bone marrow samples and survival of patients with localized neuroblastoma. *Br J Cancer*. 98 (2): 263-269, 2008. (*Impact factor: 4.115*)

Iannalfi A, Bambi F, Tintori V, Lacitignola L, Bernini G, Mariani MP, Sanvito MC, Pagliai F, Brandigi F, Muscarella E, Tapinassi F, and **Faulkner L**. Peripheral blood progenitor uncontrolled-rate freezing: a single pediatric center experience. *Transfusion*. 47 (12):2202-2206, 2007. (*Impact factor: 3.160*)

Corrias MV, **Faulkner LB**, Pistorio A, Rosanda C, Callea F, Piccolo MS, Scaruffi P, Marchi C, Lacitignola L, Occhino M, Gambini C, Tonini GP, Haupt R, De Bernardi B, Pistoia V, and Garaventa A. Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients. *Clin.Cancer Res*. 10 (23):7978-7985, 2004. (*Impact factor: 5,715*)

Bambi F, Fontanazza S, Messeri A, Lippi A, Tucci F, Tamburini A, Tintori V, Casini T, Lacitignola L, Tondo A, Veltroni M, Bernini G, and **Faulkner LB**. Use of percutaneous radial artery catheter for peripheral blood progenitor cell collection in pediatric patients. *Transfusion* 43 (2):254-258, 2003. (*Impact factor: 3.160*)

Jayne D, Passweg J, Marmont A, Farge d, Khao X, Arnold R, Hiepe F, Lisukov I, Musso M, Ou-Yang J, Marsh J, Wulfraat N, Besalduch J, Bingham SJ, Emery P, Brune M, Fassas A, **Faulkner L**, Ferster A, Fiehn C, Fouillard I, Geromin A, Greinix H, Rabusin M, Saccardi R, Scheneider P, Zintl F, Gratwohl A, and Tyndall A. Autologous stem cell transplantation for Systemic Lupus Erythematosus. *Lupus* 13 (3):168-176, 2004. (*Impact factor: 2.400*)

Pagani A, Macri L, **Faulkner LB**, Tintori V, Paoli A, Garaventa A, and bussolanti G. Detection procedures for neuroblastoma cells metastatic to blood and bone marrow: blinded comparison of chromogranin A heminested reverse transcription polymerase chain reaction to tyrosine hydroxylase nested reverse transcription polymerase chain reaction and to anti-GD2 immunocytology. *Diagn.Mol.Pathol*. 11 (2):98-106, 2002. (*Impact factor: 2.104*)

Sardi I, Tintori V, Marchi C, Veltroni M, Lippi A, Tucci F, Tamburini A, Bernini G, and **Faulkner L**. Molecular profiling of high-risk neuroblastoma by cDNA array. *Int.J Mol.Med* 9 (5):541-545, 2002. (*Impact factor: 2.090*)

**Faulkner LB**, Garaventa A, Paoli A, Tintori V, Tamburini A, Lacitignola L, Veltroni M, Lo Piccolo MS, Viscardi E, Milanaccio C, Tondo A, Spinelli S, Bernini G, and De Bernardi B. *In vivo* cytoreduction studies and cell-sorting enhanced tumor cell detection in high-risk neuroblastoma patients: implications for leukapheresis strategies. *J Clin Oncol* 18(22):3829-3836, 2000. (*Impact factor: 18.372*)

Pession A, Rondelli R, Paolucci P, Pastore G, Dini G, Bonetti F, Madon E, Mandelli F, ZanESCO L, Uderzo C, Prete A, Rabusin M, Ugazio A, Di Bartolomeo P, Favre C, **Faulkner L**, Poggi V, Luksch R, Donfrancesco A, Argioli F, La Nasa G, Amici A, and Locatelli F. Hematopoietic stem cell transplantation in childhood: report from the bone marrow transplantation group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). *Haematologica* 85(6):638-646, 2000. (Impact factor: 4.575)

van den Oudenrijn S, Bruin M, Folman CC, Peters M, **Faulkner LB**, de Haas M, and von dem Borne AE. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. *Br J Hematol* 110(2):441-448, 2000. (Impact factor: 3.267)

Bambi F, **Faulkner LB**, Azzari C, Gelli AMG, Tamburini A, Tintori V, Lippi AA, Tucci F, Bernini G, Genovese F. Pediatric peripheral blood progenitor collection: Haemonetics MCS 3p vs COBE Spectra vs Fresenius AS 104. *Transfusion* 1998;38:70-74. (Impact factor: 4.575)

**Faulkner LB**, Tucci F, Tamburini A, Tintori V, Lippi A, Bambi F, Malentacca F, Azzari C, Gelli AMG, Genovese F, Bernini G. G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective. *Bone Marrow Transplant* 1998;21:1091-1095. (Impact Factor: 3.746)

**Faulkner LB**, Tintori V, Tamburini A, Paoli A, Garaventa A, Viscardi E, Tucci F, Lippi A, De Bernardi B, Bernini G. High-sensitivity immunocytological analysis of concomitant blood and marrow tumor cell distribution in neuroblastoma. *J Hematother* 1998;7:361-366. (Impact Factor: 2.537)

**Faulkner LB**, Tamburini A, Tintori V, Paoli A, Tondo A, Bernini G, Medicina D, Brisigotti M, Corrias MV, Scaruffi P, Rosanda C, Lo Piccolo MS, Viscardi E, Milanaccio C, Garaventa A, De Bernardi B. Detection of minimal residual disease in bone marrow and peripheral blood in neuroblastoma. Prognostic and therapeutic implications. *Med Surg Ped* 1998;20:175-178.

**Faulkner LB**, Lindsley KL, Kher U, Heller G, Black P, Finlay JL. High-dose chemotherapy with autologous marrow rescue for malignant brain tumors: analysis of the impact of prior chemotherapy and cranio-spinal radiation on hematopoietic recovery. *Bone Marrow Transplant* 1996;17:389-394. (Impact Factor: 3.746)

**Faulkner LB**, Hajdu SI, Kher U, La Quaglia M, Exelby PR, Heller G, Wollner N. Pediatric desmoid tumor: retrospective analysis of 63 cases. *J Clin Oncol* 1995;13:2813-2818. (Impact Factor: 18.372)

Pini G, **Faulkner LB**. Cerebellar involvement in hypomelanosis of Ito. *Neuropediatrics* 1995;26:208-210. (Impact Factor: 1.377)

**Faulkner LB**, Finlay JL. Towards a better definition of risk-group-tailored treatment in medulloblastoma. A review of seven reports on data obtained in the computerized tomographic imaging era. *Crit Rev Neurosurg* 1994;4:13-23.

Gillio AP, **Faulkner LB**, Alter BP, Reilly L, Klafter R, Heller G, Young D, Lipton JM, Moore MAS, O'Reilly RJ. Successful treatment of Diamond-Blackfan anemia with interleukin 3. *Stem Cells* 1993;11 (suppl 2):123-130. (Impact Factor: 5.802)

Gillio AP, **Faulkner LB**, Alter BP, Reilly L, Klafter R, Heller G, Young DC, Lipton JM, Moore MAS, O'Reilly RJ. Treatment of Diamond-Blackfan Anemia with recombinant human interleukin-3. *Blood* 1993;82:744-751. (Impact Factor: 9.898)

## Other recognitions

An entire chapter dedicated to Cure2Children on Nobel Prize Professor Muhammad Yunus's book "Building Social Business: The New Kind of Capitalism That Serves Humanity's Most Pressing Needs". Chapter 4: "To Cure One Child". 2010, ISBN 978-1-58648-824-6 (hardcover).

### **Personal statement**

After working for almost 20 years in affluent counties as a pediatrician specialized in childhood cancer and blood disorders, I decided to dedicate myself full-time to international medicine. For the past 6 years I have collaborated with professionals and institutions in developing countries committed to the cure of children with cancer and severe hematological diseases. Since then this has increasingly become my primary professional objective, more at [www.cure2children.org](http://www.cure2children.org)